Dec 11, 2020 Daratumumab and bortezomib work well with novel conjugate A high percentage of patients diagnosed with relapsed or refractory multiple myeloma who have been treated with previous lines of therapy responded to investigative aminopeptide conjugate melflufen in combination with dexamethasone and either daratumumab (Darzalex) or bortezomib (Velcade), researchers found. Among 13 patients treated with melflufen (melphalan flufenamide), bortezomib, and dexamethasone, the overall response rate was 62% (8 patients) — four of those eight patients achieved a very good partial response or better, and one achieved a complete response in the ANCHOR trial, reported Enrique Ocio, MD, PhD, head of the department of hematology at University Hospital Marqués de Valdecilla, University of Cantabria, Santander, Spain.